Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1878)	1/24/2002 5:14:04 AM
From: Arthur Radley	Respond to of 2515

Miljenko, Does being arrogant come naturally for you, or do you work at it?

To: Miljenko Zuanic who wrote (1878)	1/24/2002 5:43:44 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 2515

As for your question about management selling on the open market, in all candor I wasn't aware of that this was going on to any great degree. I did note that a former executive was selling his shares....again he is a former executive. If what you indicate is true, I assume that it took place in 2001 and it might have been done for several reasons, even I sell stock for various reasons...taxes, tuition, etc. And in the case of the proposed secondary offering, that is it....proposed offering and maybe the person or persons that you allude couldn't wait until the "proposed" offering actually takes place. Thanks for bringing this issue to my attention. However, in my opinion selling stock by a company executive in an open fashion doesn't equate to a company executive blatantly lying to the public about the drug that his company is working on as in the case of IMCL. If BTRN management is engaged in borderline criminal activity as IMCL's CEO, I would appreciate you bringing this to my attention, also.

To: Miljenko Zuanic who wrote (1878)	1/24/2002 8:30:03 PM
From: Ward Knutson	Read Replies (1) \| Respond to of 2515

<<Regards the fraud, did you ask BTRN management why they were selling share at open market while proposing secondary (which may be at deep discount). Whose interest they were protecting, and working for? Miljenko>> Careful, because you don't have a clue what you are talking about. The shares registered and sold by "BTRN management" were in reality those being sold by prior management of Eligix. They did so shortly after the closing of the merger with BTRN. Careless use of the word fraud pal, there is nothing improper re: their actions. This is not unlike your prior characterization of the Irofulven Phase III as a "desperate move". Point: you portray yourself as a voice of knowledge - I would assume (on your part) a requisite, basic understanding of the facts to which you are speaking in advance of making such broad-sweeping statements. In neither of the above did you fully comprehend, or even attempt to gain insight to, the true situation(s).